14 results about "Bradycardia" patented technology

A Wearable Medical System (WMS) includes one or more pacing capabilities. The WMS may detect when the patient's heart rhythm starts to deteriorate, but not necessarily in a way that requires defibrillation. In particular, the WMS may detect bradycardia of one or more types, and then confirm the detection before pacing to treat the detected bradycardia.

1. The name of the product under this design: Pacemaker. 2. Purpose of this design product: to provide pacing function for patients with bradycardia. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The hybrid stimulation system is an electrical stimulation system serves to delivered an electrical stimulation impulse to the heart (human or animal heart) , using a combination of internal (intravascular) and external (body surface) electrodes, the hybrid electrical stimulation system can be used for pacing of the heart during slow heart beat (bradycardia), or shocking the heart during fast heart beat (Tachycardia) , or to terminate fast abnormal heart beat (tachy-arrhythmia) by means of override pacing (Anti-tachycardia pacing). This hybrid system can be used and introduced into the body without the need for imaging guidance such as fluoroscopy or echocardiography to insert the internal component, and does not require direct contact between the internal pacing wire and the myocardium (internal heart surface).

The present application relates to a pharmaceutical composition and application for improving or treating bradycardia in the field of bradycardia drug technology. In parts by weight, the pharmaceutical composition comprises the following components: 0.1-0.5 parts of fensansan extract, 30-40 parts of dextrin, 30-40 parts of corn starch, 30-40 parts of calcium hydrogen phosphate, 1-2 parts of magnesium stearate, and 1-2 parts of sodium carboxymethyl starch. The pharmaceutical composition provided in the present application has the effect of improving or treating bradycardia. When the pharmaceutical composition or the medicament prepared by the pharmaceutical composition is used to treat bradycardia, it can significantly improve the heart rate of the subject, with good therapeutic effect, and there will be no side effects of rapid arrhythmia during the treatment process, and there is no significant effect on blood pressure, which fills the gap in the clinical treatment of bradycardia. At the same time, the pharmaceutical preparation provided has a simple prescription composition, controllable process, stable and reliable product quality, long shelf life, and good application prospects.

Disclosed are a pacing control method, a pacing control apparatus, and a medical device. The pacing control method comprises: obtaining an actual heart rate of a patient; and when the actual heart rate meets a preset low heart rate condition, performing cardiac pacing on the patient by using a preset pacing frequency, the preset low heart rate condition being used for representing that the patient is in a life-critical state. The method takes the patient in the life-critical state where the heart rate is severely too slow or even cardiac arrest occurs as an object needing pacing support, and achieves the effect of timely and effectively pacing to support the life of the patient and the effect of avoiding, to a great extent, unnecessary pacing for the patient and the pain of the patient caused by pacing stimulation, especially cannot trigger pacing to occasional bradycardia, non-severe bradycardia, or transient arrest.

An implantable leadless pacemaker configured to provide antibradycardia pacing of a human or animal heart, comprising: an electrical energy source, a sensor configured to sense intracardiac potentials of the heart, a pulse generator configured to generate electrical pacing pulses, a control unit for controlling the pulse generator, wherein the control unit is configured to inhibit generation of an electrical pacing pulse when an intracardiac potential is sensed, wherein the control unit is further configured to permanently switch off the pulse generator after passing of a predetermined timespan and / or after a pre-defined event detected by the pacemaker, an electrode pole for electrical stimulation and sensing intracardiac potentials, at least one fastening element for fastening the pacemaker to heart tissue, wherein the implantable leadless pacemaker is adapted such that a lifetime of the implantable leadless pacemaker is smaller than one year, particularly smaller than one month, particularly smaller than two weeks.

A method including determining, based on an image signal received from a camera focused on at least a portion of a patient, a breathing signal, determining an onset of a desaturation event for the patient and an onset of a bradycardia event for the patient, determining length of a bradycardia-desaturation (BD) period between the onset of the desaturation event for the patient and the onset of the bradycardia event for the patient, in response to determining that the length of the BD period is less than a BD time threshold, determining whether a change in of breathing of the patient within an apnea search period indicates an apnea event, and in response to determining that the change in of breathing of the patient within the apnea search period indicates an apnea event, displaying an occurrence of an apnea-bradycardia-desaturation event.

Multiple external electrodes are used to monitor cardiac electrical activity from the patient's tissues. One or more cardiac measurements of the patient are generated based on the monitored electrical activity. If the patient has right bundle branch block, the one or more cardiac measurements are used based on a first global synchrony measure to determine whether the patient is a candidate for a cardiac resynchronization therapy (CRT) device. If the patient does not have right bundle branch block, the one or more cardiac measurements are used based on a second global synchrony measure to determine whether the patient is a candidate for a cardiac resynchronization therapy (CRT) device.

A wearable medical system (WMS) includes one or more pacing capabilities. The WMS May detect when the patient's heart rhythm starts to deteriorate, but not necessarily in a way that requires Defibrillation. In particular, the WMS may detect bradycardia of one or more types, and then confirm the detection before pacing to treat the detected bradycardia.

The hybrid stimulation system is an electrical stimulation system serves to delivered an electrical stimulation impulse to the heart ( human or animal heart ), using a combination of internal (intravascular) and external (body surface) electrodes, the hybrid electrical stimulation system can be used for pacing of the heart during slow heart beat (bradycardia), or shocking the heart during fast heart beat ( Tachycardia ), or to terminate fast abnormal heart beat (tachy-arrhythmia) by means of override pacing (Anti-tachycardia pacing). This hybrid system can be used and introduced into the body without the need for imaging guidance such as fluoroscopy or echocardiography to insert the internal component, and does not require direct contact between the internal pacing wire and the myocardium (internal heart surface).

A method for managing bradycardia through vagus nerve stimulation is provided. An implantable neurostimulator configured to deliver electrical therapeutic stimulation in both afferent and efferent directions of a patient's cervical vagus nerve is provided. An operating mode is stored, which includes parametrically defining a maintenance dose of the electrical therapeutic stimulation tuned to restore cardiac autonomic balance through continuously-cycling, intermittent and periodic electrical pulses. The maintenance dose is delivered via a pulse generator through a pair of helical electrodes via an electrically coupled nerve stimulation therapy lead independent of cardiac cycle. The patient's physiology is monitored, and upon sensing a condition indicative of bradycardia, the delivery of the maintenance dose is suspended. A progressively increasing amount of time is spent waiting via a controller and, upon sensing a condition indicative of an absence or termination of the bradycardia, a progressively increasing partial maintenance dose is delivered via the pulse generator.

An implantable medical stimulation device (1) for performing an anti-bradycardia pacing in an atrium (RA) of a patient's heart (H) comprises a generator device (12) comprising processing circuitry (120) for processing cardiac sense signals and generating cardiac stimulation signals and a housing (121), and an electrode arrangement for sensing cardiac signals and outputting cardiac stimulation signals. The electrode arrangement comprises at least one atrial electrode pole (102, 103). The processing circuitry (120) is configured to perform a rate-adaptive cardiac stimulation in which a paced heart rate is adjusted based on a load state of the patient, wherein the processing circuitry (120) is configured to obtain a momentary impedance curve (ΔZ1), to compare said momentary impedance curve (ΔZ1) to a stored reference curve (ΔZrefRest) and to perform an adaption of the paced heart rate based on the comparison of the momentary impedance curve (ΔZ1) to the stored reference curve (ΔZrefRest). The processing circuitry (120) is configured to obtain said momentary impedance curve (ΔZ1) by conducting a unipolar impedance measurement between the at least one atrial electrode pole (102) and the housing (121).

To enable a user to grasp occurrence of delayed transient bradycardia in a fetus prior to actual occurrence of delayed transient bradycardia in the fetus.SOLUTION: Using a temporal change in a cardiac rate of a fetus measured in a pre-occurrence period of bradycardia BDP, which is a period before a predetermined time I from a bradycardia occurrence time point tLD that delayed transient bradycardia LD previously occurred in the fetus, as learning data, a learning model 30 performs learning so as to predict whether delayed transient bradycardia LD occurs in the fetus after the predetermined time I from the pre-occurrence period of bradycardia BDP, and outputs the result. A delayed transient bradycardia prediction part 32 inputs a temporal change in a fetus cardiac rate of an object fetus in an object period TP to the learning model 30 that has learned, and predicts whether the delayed transient bradycardia occurs in the object fetus at a prediction object time point tPT on the basis of the output data of the learning model 30 for the input data. An output control part 24 notifies a user of a fact that it is predicted that the delayed transient bradycardia occurs in the object fetus, when it is predicted that the delayed transient bradycardia occurs in the fetus.SELECTED DRAWING: Figure 1